Siklos

Nordic Pharma has launched Siklos (hydroxycarbamide) for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in paediatric and adult patients suffering from symptomatic sickle cell syndrome.

Hydroxycarbamide is an antineoplastic agent. The specific mechanism of action in the treatment of sickle cell syndrome is not fully understood, but hydroxycarbamide elevates fetal haemoglobin (HbF) concentrations in patients with sickle cell syndrome.

Recently, hydroxycarbamide has shown to be associated with the generation of nitric oxide suggesting that nitric oxide stimulates cyclic guanosine monophosphotase production, activating a protein kinase and increasing the production of HbF.

View Siklos drug record

Further information: Nordic Pharma

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Reversal of benefits after novel migraine prophylactics stopped, study shows

Reversal of benefits after novel migraine prophylactics stopped, study shows

Findings from a recent study indicate a return to pre-treatment...

New products - live tracker

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

Deleted products - live tracker

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...